Hypertension Congress
Already Registered? Login Here
For healthcare professionals only in markets where the Symplicity™ Renal Denervation System is approved.
Time Title Facilitator

11.15 CET

Welcome & Update from the International Society of Hypertension Scientific Meeting 2012 Professor Markus Schlaich
Course Chair
Baker IDI Heart & Diabetes Institute, Melbourne, Australia

12.00 CET

Sympathetic Activity in the Pathophysiology of Hypertension Professor Krzysztof Narkiewicz
Medical University of Gdansk,
Gdansk, Poland

13.00 CET

Treatment-Resistant Hypertension:
Definition, Prevalence, Diagnosis, and Pharmacotherapy
Professor Luis Ruilope
12 de Octubre Hospital,
Madrid, Spain

14.00 CET

Symplicity™ Renal Denervation System:
Examining the Evidence and Understanding the Procedure
Professor Michael Böhm
University Hospital of Saarland, Homburg/Saar, Germany

15.00 CET

Practical Considerations for Patient Identification and RDN Program Implementation:
A Case-Based Approach
Professor Markus Schlaich
Professor Michael Böhm,
Professor Krzysztof Narkiewicz,

Professor Luis Ruilope

Professor Markus Schlaich (Chair)

Professor Markus Schlaich is a nephrologist with a specific interest in hypertension, its causes and consequences. Schlaich has a strong clinical research background in hypertension, nephrology and cardiovascular disease, and is an author on more than 130 peer-reviewed articles and book chapters. He has a specific interest in treatment modalities targeting the sympathetic nervous system and has contributed to the development of renal denervation as a novel therapeutic approach to hypertension. He currently heads the "Neurovascular Hypertension & Kidney Disease Laboratory" at the Baker Heart Research Institute and acts as Director of the Alfred & Baker Hypertension Network. He also holds an NHMRC Senior Research Fellowship and an academic appointment with the Department of Medicine of Monash University and serves on the Executive Committee of the High Blood Pressure Research Council of Australia.

Professor Dr Michael Böhm

Michael Böhm performed his medical training at the Medical School of Hannover in Germany. He went on to conduct his residency in internal medicine and fellowships in cardiology at the Ludwig Maximilians-University in Munich, Germany at the Klinikum Großhadern; Heisenberg Graduate of the Deutsche Forschungsgemeinschaft; Assistant and Associate Professor of Internal Medicine and Cardiology at the Universität zu Köln in Germany. Since 2000, he has been the Director of the Klinik für Innere Medizin III and Chief of Cardiology at the University of the Saarland in Homburg/Saar, Germany. Professor Böhm's special interests include pathophysiology and therapy of heart failure. In particular, he is involved in studies on signal transduction in the failing heart and in vascular biology. Professor Böhm has been the principal investigator in several international multicenter studies including the SHIFT-trial. He has written more than 350 original papers, book chapters and review articles. He has obtained several awards from scientific societies. Professor Böhm is a reviewer for most recognized scientific journals in the cardiovascular field and chief editor Clinical Research in Cardiology. He is president of the German Society of Cardiology.

Professor Krzysztof Narkiewicz

Krzysztof Narkiewicz graduated in Medicine from the Medical University of Gdansk, Poland in 1988, and obtained his Ph.D. from the same university in 1993. He was a visiting scientist of the National Institutes of Health at the University of Iowa in Iowa City, USA (1996-1998). He is currently Professor of Internal Medicine in the Department of Hypertension and Diabetology, and the Head of the Hypertension Unit at the Medical University in Gdansk.

His research has focused on the role of the sympathetic nervous system and metabolic factors in regulation of cardiovascular function in physiological and pathological states, including hypertension, coronary artery disease, congestive heart failure, obstructive sleep apnea, and syncope. Recently, much of his activity has been related to the prevention and treatment of hypertension, hyperlipidemia, congestive heart failure, and diabetes. His current projects include large clinical trials in hypertension, obesity-related hypertension, and the role of patient education in treatment of hypertension and diabetes. He was the Polish national coordinator of several trials including SCOUT, IDEA, and INSPIRE ME. He has served as a member of various international trial Data Safety Monitoring Boards including ROADMAP and HYVET.

Professor Narkiewicz has published over 180 papers mainly in the areas of hypertension, cardiovascular disease and metabolic disorders (total Impact Factor >500, total number of citations >5300). He is the editor of Blood Pressure, a journal endorsed by the European Society of Hypertension; he is on the editorial board of 12 journals. Professor Narkiewicz has received various medical awards including the Austin Doyle Award of the International Society of Hypertension (2000). Since 2003, he has been a Polish national consultant in the clinical management of hypertension. Narkiewicz has served in multiple medical society leadership roles including: member of the Scientific Council of the Polish Society of Hypertension; member of the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), preparing the 2007 Guidelines for the Management of Arterial Hypertension; and Immediate Past President of the Scientific Council of the European Society of Hypertension (2009-2011).

Professor Luis Ruilope

Professor Ruilope is Associate Professor of Internal Medicine at Complutense University and Head of the Hypertension Unit at the 12 de Octubre Hospital in Madrid, Spain. His principal area of interest is hypertension and the kidney. Professor Ruilope received his MD degree from the University of Madrid and completed his residency and fellowship in nephrology at the Jiménez Díaz Foundation in Madrid.

A member of the Scientific Council of the International Society of Hypertension and an International Fellow of the Council of High Blood Pressure Research, Professor Ruilope is on the editorial boards of the Journal of Hypertension, Blood Pressure, High Blood Pressure & Cardiovascular Prevention, Medicina Clinica, Nephrology Dialysis Transplantation, and the Journal of Human Hypertension.

He is a board member of the Spanish Society of Hypertension and a member of the Council on the Kidney in Cardiovascular Disease (American Heart Association). He served on the ISH 2000 International Scientific Program Committee and was a member of the Steering Committee in the studies Hypertension Optimal Treatment (HOT), INtervention aS a Goal In HyperTension (INSIGHT), Study on Cognition and Prognosis in the Elderly (SCOPE), and Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE).


For healthcare professionals only in markets where the Symplicity™ Renal Denervation System is approved.

Need assistance with this form?

Learning Objectives

  • Identify and select the appropriate patients for renal denervation
  • Understand the sympathetic nervous system and its role in hypertension
  • Explain the epidemiology and pathophysiology of resistant hypertension
  • Discuss the body of evidence that supports pharmacologic and device-based approaches for treating resistant hypertension
  • Develop practical strategies for implementing an integrated clinical team approach to treating patients with resistant hypertension